{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-019590","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2022-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.474919+00:00","generated_at":"2026-06-25T11:36:05.842621+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aquestive CEO Keith Kendall departs; COO Daniel Barber named President & CEO","bullets":["Keith Kendall leaves as President, CEO, and Board member effective May 17, 2022.","Daniel Barber, former COO (since May 2019), appointed President, CEO, and Class I Director.","Kendall receives severance: $262,500 accelerated first three installments plus monthly payments, and $10,000/month consulting fee through Dec 2022.","Kendall will serve as consultant to assist in management transition through end of 2022.","Company states Kendall's departure is unrelated to strategy, operations, or financial condition."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-019590","json":"https://secwatch.observer/filing/0001140361-22-019590.json","markdown":"https://secwatch.observer/filing/0001140361-22-019590.md","text":"https://secwatch.observer/filing/0001140361-22-019590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/brhc10037837_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T11:36:05.842621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6fcec6364f","claim":"Daniel Barber was appointed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..","evidence_excerpt":"Effective May 17, 2022, the Board appointed Daniel Barber, Senior Vice President and Chief Operating Officer of the Company, to the position of President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"76f5bc6a47","claim":"Keith J. Kendall departed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..","evidence_excerpt":"On May 17, 2022, Aquestive Therapeutics, Inc. (the “Company”) announced that Keith J. Kendall, President and Chief Executive Officer of the Company, is leaving the Company and Board of Directors (the “Board”) effective May 17, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"leaving"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f30267fdc1","claim":"Daniel Barber was appointed as Class I Director at Aquestive Therapeutics, Inc..","evidence_excerpt":"In addition, the Board appointed Mr. Barber to fill the vacancy on the Board due to Mr. Kendall’s departure, to serve as a Class I Director with a term expiring at the Company’s 2022 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}